Triggering the Immune System: Immune Checkpoint Inhibitors for the Treatment of Non–Small Cell Lung Cancer

This activity contains:

  • CME/CPE/CNE-Certified Live Grand Rounds and Webinars
  • Downloadable Slide Deck (a non-certified educational resource)

Purpose
The goal of this activity is to provide clinicians with the latest developments and clinical data available regarding immunotherapy for the treatment of NSCLC.

Activity Overview
In 2016, there were an estimated 224,390 new cases of lung and bronchus cancer in the United States, making it the second most commonly diagnosed cancer in both men and women and accounting for 14% of all cancer diagnoses. Lung and bronchus cancer is the leading cause of cancer-related deaths in the United States among both men and women, with an estimated 158,080 deaths expected to occur in 2016.

Advances in immunotherapy are revolutionizing the way clinicians treat and manage lung cancer. As of October 2016, 3 checkpoint inhibitors approved by the US Food and Drug Administration (FDA) for the treatment of non–small cell lung cancer (NSCLC), nivolumab, pembrolizumab, and atezolizumab.  Several other checkpoint inhibitors also are being investigated for their effectiveness in treating lung cancer. 

This activity will review the latest developments and clinical data available regarding immunotherapy for NSCLC to help clinicians remain up-to-date about this important topic and provide state-of-the-art care to their patients.

Activity Agenda

  • Activity Overview
  • Role of the Immune System in Cancer
  • Mechanism of Action of Immune Checkpoint Inhibitors in NSCLC
  • Immune Checkpoint Inhibitors for the Treatment of NSCLC
  • Managing and Monitoring Side Effects and Adverse Events of Immune Checkpoint Inhibitors
  • Conclusion and Q&A

Target Audience

This activity is intended for academic and community medical oncologists, pulmonologists, advanced practice registered nurses, nurses, and pharmacists who treat lung cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the role of the immune system as a target to treat cancer
  • Identify the mechanisms of action of immune checkpoint inhibitors for the treatment of non–small cell lung cancer to select optimal therapy and educate patients and their families about how these agents work
  • Select immune checkpoint inhibitors for the treatment of patients with non–small cell lung cancer based on current evidence, best practices, and patient/family choices
  • Develop approaches for the early identification and management of side effects and adverse events that can occur with immune checkpoint inhibitors to improve patient outcomes
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance
Course opens: 
12/21/2016
Course expires: 
05/09/2018
Cost:
$0.00
Rating: 
0

Chairperson

Shirish M. Gadgeel, MD
Director of the Thoracic Oncology Research Team
Professor, Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Faculty Speakers

Christopher G. Azzoli, MD 
Assistant in Medicine
Massachusetts General Hospital Cancer Center
Boston, MA

Hossein Borghaei, DO
Chief Thoracic Medical Oncologist
Associate Professor
Fox Chase Cancer Center
Philadelphia, PA

Patrick Forde, MD
Assistant Professor Oncology
Johns Hopkins University
Baltimore, MD

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center /Yale School of Medicine 
Smilow Cancer Hospital at Yale
New Haven, CT

Ronan Kelly, MD, M.B.B.Ch., M.B.A.
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD 

Jarushka Naidoo, MD
Assistant Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD 


Continuing Education
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
 


Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit. UAN 0592-0000-17-001-L01-P .

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.

Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour. 

Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or PresenterReported Financial Relationship
Shirish M. Gadgeel, MDShirish M. Gadgeel, MD  reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Bristol-Myers Squibb Co, Astra Zeneca, Ariad Pharmaceuticals, Genentech/Roche; Speakers bureau, Astra Zeneca Pharmaceuticals, Genentech, Inc.
Christopher G. Azzoli, MD    Christopher G. Azzoli, MD, has no real or apparent conflicts of interest to report.
Hossein Borghaei, DOHossein Borghaei, DO, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Bristol-Myers Squibb Company, EMD Serono, Inc., Genentech, Inc., Lilly USA, Merck & Co., Inc., Pfizer, Inc., Trovogene; Research grant, Millennium Pharmaceuticals, Merck & Co., and Celgene.
Patrick FordePatrick Forde, MD reported a financial interest/relationship or affiliation in the form of Received research grant from, Bristol-Myers Squibb Co., Astra Zeneca Pharmaceuticals, Kyowa Kirin Pharmaceuticals, and Novartis Pharmaceuticals; Consultant, Bristol-Myers Squibb Co., Astra Zeneca Pharmaceuticals.
Roy S. Herbst, MD, PhDRoy S. Herbst, MD, PhD reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Biothera, Diatech Pharmacogenetics, Kolltan Pharmaceuticals, Astra Zeneca Pharmaceuticals, Eli Lilly USA, Genentech/Roche, Inc,Pfizer Inc.; Clinical trial support/grant, Genentech, Inc., Merck & Co. 
Ronan Kelly, MD, MBBCh, MBA  Ronan Kelly, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, EMD Serono, Inc., Lilly USA.Research grant, Bristol-Myers Squibb Company; and , AstraZeneca Pharmaceuticals LP.
Jarushka Naidoo MDJarushka Naidoo MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, MedImmune.Speakers' bureau, CHEST, SITC, AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., AstraZeneca Pharmaceuticals 


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

This activity is supported by an educational grant from Genentech.

There is no fee for this educational activity.

This activity is provided by:

AXIS 1502

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 Attendance

Accreditation Period

Course opens: 
12/21/2016
Course expires: 
05/09/2018

Price

Cost:
$0.00
Please login or register to take this course.